The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) adopted new safety recommendations for several medicines during its meeting from 7 to 10 April 2026, the agency announced on 4 May 2026. The recommendations include updates to product information, restrictions on use, or additional monitoring requirements for specific drugs, impacting healthcare professionals, patients, and marketing authorisation holders across the EU.
The PRAC meeting, held at EMA's headquarters in Amsterdam, reviewed signals of potential adverse reactions or new safety concerns. While the full list of medicines and specific recommendations has not been detailed in the announcement, the committee's decisions typically involve updating the summary of product characteristics and package leaflets, or imposing temporary restrictions. The recommendations are not legally binding but are expected to be formally endorsed by the European Commission and implemented by national competent authorities within a set timeframe.
Stakeholder impact
Healthcare professionals will need to adapt prescribing practices and inform patients of any new risks. Patients may face changes in how their medicines are used or monitored. Marketing authorisation holders must update product information and communicate changes to regulators. EU national authorities are responsible for enforcing the recommendations and ensuring compliance.
Next steps
The PRAC recommendations will be forwarded to the Committee for Medicinal Products for Human Use (CHMP) for final opinion, and subsequently to the European Commission for a legally binding decision. The full details of the signals and recommendations are expected to be published in the next edition of EMA's monthly pharmacovigilance bulletin.